Table 3. Differentially expressed (canonical activation) genes between p65high vs. p65low patients with diffuse large B-cell lymphoma (DLBCL).
| p65high vs. p65low | |||
|---|---|---|---|
| Functional categories | In overall DLBCL (FDR <0.30) |
In GCB-DLBCL (FDR <0.05) | In ABC-DLBCL (FDR <0.20) |
| Signaling, ion channels | TNFRSF1A ↑ FYN ↑ LCP2 ↑ PTPRD ↑ GTPBP2 ↑ PROCR ↑ TENC1 ↑ ITPR3 ↑ TEK ↑ CACNA2D1 ↑ AGTRAP ↑ LPAR3 ↓ | MT1X ↑ MT1G ↑ SERPING1 ↑ PSEN1 ↑ | ARHGEF2 ↑ FGFBP1 ↑ EPHA1 ↑ MS4A3 ↑ |
| Immune responses, inflammation | CD163 ↑ FCER1G ↑ CYBB ↑ GRN ↑ CD84 ↑ LILRB1 ↑ | DEFB4 ↑ | |
| Cell cycle, DNA metabolism, transcription and translation regulation | JUN ↑ MLLT10 ↑ GATAD2A ↑ HOXD10 ↑ NFRKB ↑ ZWINT ↓ MCM10 ↓ HMGB1 ↓ PPP2CA ↓UHRF1 ↓ BTG3 ↓ ZNF254 ↓ CARS ↓ PA2G4 ↓ SERBP1 ↓ | RBMS1 ↑ ANKRD11 ↑ FAM89B ↑ | ESRP1 ↑ DPPA4 ↑ |
| Apoptosis | PMAIP1 ↓ BIRC6 ↓ | RNF130 ↑ | |
| Metabolism | SULT1A1 ↑ SPTLC2 ↑ SLC25A16 ↑ SLC9A9 ↑ | GLUL ↑ SERINC1 ↑ CAT ↑ SLC9A9 ↑ | S100A16 ↑ SLC9A5 ↑ |
| Transport, trafficking, protein folding, chaperone | CPNE8 ↑ DNAJC5 ↑ RHD ↑ AGFG2 ↑ | SLC8A1 ↑ NPC2 ↑ VAMP5 ↑ DNAJC5 ↑ | |
| Cell adhesion, cytoskeleton, collagen, extracellular matrix | SH3D19 ↑ ITGA6 ↑ MYLK ↑ COL6A1 ↑ UTRN ↑ FMOD ↑ | UTRN ↑ | CCDC151 ↑ KRT13 ↑ ANTXR2 ↑ COL17A1 ↑ |
| Degradation, ubiquitination | RNASE1 ↑ | SCARB2 ↑ CTSB ↑ UBA7 ↑ | PSMB1 ↑ |
| IncRNA genes, unknown function | NCRNA00185 ↑ C19orf6 ↑ PLEKHO2 ↑ FAM124A ↑ | MT1P2 ↑ ZDHHC20 ↑ PLEKHO2 ↑ | FAM105B ↓ CG030 ↑ NCRNA00185 ↑ IQCG ↑ |
Abbreviations: p65high, p65 immunohistochemistry results: ≥50% nuclear expression; p65low, p65 immunohistochemistry results: <50% nuclear expression; GCB, germinal center B-cell–like; ABC, activated B-cell–like; FDR, false discovery rate. *Upregulated genes in bold.